Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. introduces cathepsin K inhibitors

Aug. 31, 2015

Lilly patents GPR142 agonists

Aug. 31, 2015

Novel FFAR4 agonist shows glucose-lowering effect in vivo

Aug. 31, 2015

ProMetic expands PBI-4050 metabolic syndrome trial after safety review

Aug. 28, 2015

FDA approves Amgen's Repatha

Aug. 28, 2015

FDA approves empagliflozin/metformin for type 2 diabetes

Aug. 28, 2015

Adocia and Lilly begin phase Ib study of ultra-rapid BioChaperone Lispro

Aug. 28, 2015

Novo Nordisk begins phase IIIa development of oral semaglutide

Aug. 27, 2015

Janssen Pharmaceutical presents FFAR4 agonists

Aug. 27, 2015

Amgen submits NDA for etelcalcetide

Aug. 26, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...